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ABSTRACT
Advances and success in cloning and genetic
engineering may mean passenger pigeons, dodos, gastricbrooding frogs, thylacines, woolly mammoths, and other
extinct species will once again grace this planet. As deextinction becomes a reality, it is uncertain whether these
animals are patent eligible. Diamond v. Chakrabarty
opened the door to cloning multicellular organisms. Since
then, the U.S. Patent Office’s Board of Patent Appeals and
Interferences has found “non-naturally occurring, manmade organisms including animals” to be patentable
subject matter under 35 U.S.C. § 101. Because the initial
case challenging this decision failed on procedural
grounds, the underlying legal issue has not been addressed
in a federal court. Congress forbids patents directed at, or
encompassing, human organisms, but has been silent with
respect to animals. The Supreme Court holds that sections
of naturally occurring DNA are not patent eligible, while
non-naturally occurring synthetic strands are. But the
*
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Court has not considered organisms created from both
naturally occurring and synthetic DNA, as would be the
case in de-extinction. The Federal Circuit upheld a
decision denying a patent for Dolly the cloned sheep, yet
left room for successful patents of other cloned animals.
The Federal Circuit’s distinction may lie between patenting
the clone of an animal that already exists and patenting an
animal that does not or no longer exists. In light of everchanging science and technology, there are few clear
boundaries of what organisms can or cannot be patented.
Practitioners need to be aware of the boundaries and the
gray areas in the existing law to navigate a path towards
patentability of de-extinct species.
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INTRODUCTION
The ability to successfully reintroduce a previously extinct
animal is no longer confined to the pages of Jurassic Park.1 The deextinction movement is beginning to bring species back from
extinction, through cloning and genetic engineering. In 1996,
scientists successfully cloned a complex mammal, Dolly the
sheep.2 Seven years later, Spanish and French scientists harvested
DNA from the recently extinct Pyrenean ibex (the Spanish
burcardo) and became the first scientists to clone an extinct
animal.3 Earlier this year, geneticists inserted the DNA of a woolly
mammoth into lab-grown elephant cells.4
The motivation behind de-extinction is both pragmatic and
fanciful. Supporters of de-extinction argue that species
reintroduction carries the potential of medical and pharmaceutical
discoveries.5 De-extinction allows for preservation and reestablishment of ecosystems in danger of or already lost to
extinction.6 Humanity is remorseful over the species that have been
lost. There is a powerful and compelling desire to see animals that
only exist in museums and the pages of books, alive and returned
to the wild.
Skeptics point to the instability of reintroducing an animal
species into an environment no longer hospitable to its survival.7
They caution that bringing back species may decrease the urgency
1

MICHAEL CRICHTON, JURASSIC PARK (1990).
ROSLIN INST., U. EDINBURGH, Dolly the Sheep: A Life of Dolly,
http://www.roslin.ed.ac.uk/public-interest/dolly-the-sheep/a-life-of-dolly/ (last
updated Apr. 7, 2015).
3
Carl Zimmer, Bringing Them Back to Life, NAT’L GEO. (Apr. 2013),
available at http://ngm.nationalgeographic.com/2013/04/125-species-revival/
zimmer-text.
4
Tanya Lewis, Woolly Mammoth DNA Inserted into Elephant Cells, LIVE
SCI. (Mar. 26, 2015, 5:42 PM), http://www.livescience.com/50275-bringingback-woolly-mammoth-dna.html.
5
Zimmer, supra note 3.
6
Id.
7
Stuart Pimm, Opinion: The Case Against Species Revival, NAT’L
GEOGRAPHIC NEWS (Mar. 12, 2013), http://news.nationalgeographic.com/
news/2013/03/130312--deextinction-conservation-animals-science-extinctionbiodiversity-habitat-environment.
2
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of protecting fragile ecosystems, and warn about unintended
consequences of interfering with established ecosystems.
The methods used for de-extinction are patent eligible, but
patent eligibility for the re-created animals themselves is uncertain.
This Article examines the potential for obtaining patents on extinct
animals that have been re-created through cloning and genetic
engineering. First, it explores the evolution of patent protection for
living organisms. Next, it explores the scientific techniques
currently being used to bring extinct species back into existence.
Finally, it discusses the probability and potential hurdles to
obtaining a patent on a re-created animal. Ultimately, successful
applications for patents on these animals must first demonstrate
that the resulting animal has characteristics (structural, functional,
or otherwise) that are different from its extinct predecessor.
I. LIVING ORGANISMS AND 35 U.S.C. § 101
A. Non-Naturally Occurring Plants Are Patent Eligible Material
Title 35, Section 101 of the U.S. Code defines patentable
inventions as “any new and useful process, machine, manufacture,
or composition of matter, or any new and useful improvement
thereof . . . .”8 The Plant Patent Act of 1930 establishes that living
organisms are not precluded from patent eligibility.9 The Act
specifies that “[w]hoever invents or discovers and asexually
reproduces any distinct and new variety of plant” can obtain a
patent on it.10 In passing the legislation, Congress explained that
the work of “the plant breeder ‘in aid of nature’ was patentable
invention.”11 But in 1948, the United States Supreme Court held
that naturally occurring, living organisms are not patentable,
regardless of whether they are selected or mixed in a way not
found in nature.12 In Funk Bros., a manufacturer sought a patent
8

35 U.S.C. § 101 (2006).
35 U.S.C. § 161 (2006).
10
Id.
11
Id. at 312 (quoting S. REP. NO. 315, at 6–8 (1930) (Conf. Rep.); H.R. REP.
NO. 1129, at 7–9 (1930) (Conf. Rep.)).
12
Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948).
9
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for a mixture of strains of bacteria that helped certain plants extract
nitrogen from the air and fix it into the soil.13 The Court held that
the mixture was not eligible for a patent because the bacteria used
in it was scientifically unaltered and found in nature.14 Congress
later sanctioned patent protection for certain sexually reproduced
plants with the 1970 Plant Variety Protection Act.15
B. The Supreme Court Expands the Scope of Patent Eligible
Organisms
Diamond v. Chakrabarty challenged the United States Patent
and Trademark Office’s (“USPTO”) denial of certain bacteria
patent claims. The USPTO reasoned that bacteria were precluded
from patent eligible material under § 101 because (1)
microorganisms are “products of nature” and (2) living things are
not patent eligible.16 The Supreme Court rejected this reasoning,
concluding that the statutory category of “composition of matter”
includes living organisms and is not limited by the Plant Protection
and Plant Variety Protection Acts.17 Furthermore, the Court held
that science and technology are not precluded patent protection
simply because such methods were not conceptualized when §101
was enacted.18
Shortly after the Chakrabarty ruling, the USPTO issued two
rulings through its Board of Patent Appeals and Interferences
(“B.P.A.I.”), expanding the definition of patentable subject
material. In the first, Ex parte Hibberd, the B.P.A.I. held that entire
plants and tissue cultures are patentable subject material.19 A few
years later in Ex parte Allen, the B.P.A.I. established that nonnaturally occurring animals are patent eligible.20
13

Id.
Id. (“[P]atents cannot issue for the discovery of the phenomena of
nature.”).
15
Diamond v. Chakrabarty, 447 U.S. 303, 313 (1980).
16
Id. at 306.
17
Id. at 311.
18
Id. at 318.
19
Ex Parte Hibberd, 227 U.S.P.Q 443, 1985 WL 71986 (B.P.A.I. Sept. 24,
1985).
20
Ex Parte Allen, No. 86-1790, 1987 WL 123816 (B.P.A.I. Apr. 3, 1987),
14
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The USPTO followed these rulings with a notice reiterating
that “[t]he Patent and Trademark Office now considers nonnaturally occurring, nonhuman, multicellular, living organisms,
including animals, to be patentable subject matter.”21 The USPTO
placed a moratorium on granting subsequent patents on animals to
give Congress time to debate the issues involved, weigh concerns
from the public, and prescribe changes to the laws.22 No such
hearings occurred.
Eight months later, the USPTO lifted the moratorium and
issued the first patent for a genetically modified animal: “the
Harvard mouse.”23 The Harvard mouse triggered public concern
and outrage.24 The controversy over this patent led animal rights
organizations and concerned farmers to challenge the USPTO’s
interpretation of the patent statute.25 Legal action was initiated, but
the case was dismissed on standing grounds.26 To date, the
Supreme Court has not addressed the substantive question of
whether transgenic animals should be patentable.
C. The Boundaries of Obtaining Patents on Living Organisms
1. Products of Nature Are Not Patent Eligible Subject Matter
The scope of patentable subject matter in the United States is
not without limits. Laws of nature, principles, physical phenomena,
abstract ideas, and products of nature are not patent eligible.27 In
particular, the Product of Nature doctrine prevents things already
existing in nature from being patentable subject matter. However,
it is not clear what falls within the scope of being a “product of
aff’d, 846 F.2d 77 (Fed. Cir. 1988).
21
Animals – Patentability, 1077 Off. Gaz. Pat. & Trademark Office 24
(Apr. 21, 1987).
22
36 PAT. TRADEMARK & COPYRIGHT J. (BNA) No. 888, at 271–72 (1988).
23
U.S. Patent No. 4,736,866 (filed June 22, 1984) (issued Apr. 12, 1988).
24
Elizabeth Hecht, Note, Beyond Animal Legal Defense Fund v. Quigg: The
Controversy Over Transgenic Animal Patents Continues, 41 AM. U. L. REV.
1023, 1041-44 (1992).
25
Animal Legal Def. Fund v. Quigg, 932 F.2d 920 (Fed. Cir. 1990).
26
Id.
27
Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
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nature.” In the wake of Chakrabarty, courts apply the doctrine as
an inquiry into whether a naturally occurring product has been
changed or altered to the extent that the claimed form does not
exist in nature.28 This effectively limits what is a non-patent
eligible, “product of nature.” The Supreme Court emphasizes that
“the relevant distinction [is] not between living and inanimate
things, but between products of nature, whether living or not, and
human-made inventions.”29 A composition of matter that occurs in
nature will be considered patentable if given a new form, quality,
properties, or combination not present in the original article.30
Anything can be deemed “made by man” so long as it does not
occur naturally without the interference of man. In Funk Bros. and
Chakrabarty, the Supreme Court offers examples of what is and
what is not a product of nature, but the distinction is murky and not
easily defined.31
After Chakrabarty, the Product of Nature doctrine does not
present a significant hurdle to patent eligibility in the USPTO or
the courts. The USPTO began granting patents on naturally
occurring DNA sequences that were “isolated” or “purified,”
arguing that excised genes do “not occur in that isolated form in
nature” and the “purified state is different from the naturally
occurring compound.”32 In 2013, the USPTO’s stance was
challenged in Ass’n for Molecular Pathology v. Myriad Genetics,
Inc. Relying on the Product of Nature doctrine, the Supreme Court
held that naturally occurring, isolated DNA segments are not
28

Jerzy Koopman, The Patentability of Transgenic Animals in the United
States of America and the European Union: A Proposal for Harmonization, 13
FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 103, 123 n.79 (2002) (quoting E.S.
VAN DE GRAAF, PATENT LAW AND MODERN BIOTECHNOLOGY: A COMPARATIVE
STUDY ABOUT THE REQUIREMENTS AND THE SCOPE OF PROTECTION 28 (1997)).
29
J.E.M. Ag Supply, Inc. v. Pioneer HI-Bred Int’l., Inc., 534 U.S. 124, 134
(2001) (quoting Diamond v. Chakrabarty, 447 U.S. 303, 311–12 (1980)).
30
Chakrabarty, 447 U.S. at 308.
31
See, e.g., Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127
(1948) (finding that mixing together pre-existing bacteria in a manner that is not
found in nature is still a product of nature); Diamond v. Chakrabarty, 447 U.S.
303 (1980) (finding that inserting DNA into bacteria to produce an organism
that is not found in nature is not product of nature).
32
Utility Examination Guidelines, 66 Fed. Reg. 1092, 1093, I(2) (Jan. 5,
2001).
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patent eligible although,
segments of DNA are.33

non-naturally occurring synthetic

2. Cloned Organisms Are Generally Not Patentable Subject
Matter
In general, cloned animals are not patent eligible. The Federal
Circuit Court of Appeals upheld the USPTO’s denial of a patent
application for the first cloned mammal, Dolly the sheep.34 The
court based its ruling on the fact that Dolly is an exact genetic
replica of an existing animal; therefore, her “genetic identity to her
donor parent renders her unpatentable.”35 Despite the ruling, the
decision leaves potential for obtaining patents on cloned animals.
The court specifies that “having the same nuclear DNA as the
donor mammal may not necessarily result in patent ineligibility in
every case,” emphasizing that at a minimum the clone must have
“markedly different characteristics from the donor" of which it is a
copy.36
Success in genetic engineering and advances in cloning have
opened the possibility of bringing species of animals back from
extinction, raising questions about whether these animals will be
patent eligible under existing patent law. These re-created animals
previously existed in nature but as a result of human behavior, or
other events, are now extinct and no longer exist in nature. Their
re-creation is entirely dependent upon the intervention of man with
the ultimate goal of creating a genetic match to the original
species. The process fails to fall neatly within the Product of
Nature doctrine, pushing at its already tenuous boundaries.

33

Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107,
2115–20 (2013).
34
In re Roslin Inst., 750 F.3d 1333 (Fed. Cir. 2014).
35
Id. at 1337.
36
Id. at 1339.
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II. THE SCIENCE OF DE-EXTINCTION
A. Cloning As a Tool For De-Extinction
De-extinction through cloning begins with the removal of DNA
from the preserved tissue specimen of an animal. The original
DNA must be intact and without any deterioration.37 The DNA is
placed into the nucleus of a reproductive egg from another animal
that has been cleared of its own genetic material.38 The cell is
manipulated to begin dividing and eventually the embryo is placed
into a surrogate mother of a compatible species.39 The resulting
animal is the genetic twin of the donor animal.
Part of the difficulty of cloning extinct animals is the fact that
DNA typically undergoes some level of decay, depending on how
long the species has been extinct. Animals recently extinct or atrisk of extinction are the best candidates for cloning. The DNA
used with the Pyrenean ibex clone in Spain was obtained from the
last living ibex, Celia, shortly after she died.40 Nonetheless, the
fragility of DNA limits the broad application of cloning as a means
for de-extinction.
B. Genetic Engineering of Extinct Species
Genetic engineering techniques address the problems of DNA
decay in extinct animals. Scientists compare the mapped DNA
obtained from extinct animals with the DNA of similar, nonextinct animals to identify key mutations that differentiate the two
species.41 Germ cells are stimulated from the similar or compatible
species.42 Strands of DNA matching the extinct animal are
37

Brian Switek, How to Resurrect Lost Species, NAT’L GEOGRAPHIC
NEWS (Mar. 11, 2013), http://news.nationalgeographic.com/news/2013/13/
130310-extinct-species-cloning-deextinction-genetics-science.
38
Id.
39
Id.
40
Zimmer, supra note 3.
41
Id.
42
Nathaniel Rich, The Mammoth Cometh, N.Y. TIMES MAG. (Feb. 27,
2014),
http://www.nytimes.com/2014/03/02/magazine/the-mammothcometh.html?_r=1.
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synthetically created and then “cut and pasted” into the DNA in the
germ cells of the similar species in order to make it function like
the extinct animal’s DNA.43 These germ cells are placed into an
embryo of the compatible species integrating into that animal’s
reproductive organs.44 The embryo will grow normally, but it now
carries eggs or sperm of the reconstructed extinct animal.45
Breeding two of these “chimeras” will result in the birth of the
once extinct animal.46
Genetically restored extinct animals could be a reality by 2020
and clones of recently extinct animals could exist sooner.47
Although patent eligibility of de-extinct animals is uncertain,
patent eligibility for the processes of de-extinction is not in
question. Dolly is not patent eligible, but the Roslin Institute holds
a patent on the method used to clone her.48 The question remains:
can the genetic re-creation of an animal that previously existed in
nature be patent eligible?
III. THE PROBABILITY OF PATENT ELIGIBILITY
An animal generated through the de-extinction process could
be deemed patent eligible. The re-created animal will not be an
exact genetic copy of an animal that already exists and will have
different structural characteristics than the original species.
Therefore, no precedent forbids it and the trend of patent law is
permissive in this area.
A. The Arguments in Favor of Patent Eligibility
Re-created extinct animals will have markedly different
characteristics than the original animal, rendering them an
exception to the Product of Nature doctrine and therefore, patent
eligible. Patents are currently granted for transgenic animals
43

Id.
Id.
45
Id.
46
Id.
47
Zimmer, supra note 3.
48
In re Roslin Inst., 750 F.3d 1333 (Fed. Cir. 2014).
44
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created for medical and scientific research.49 Furthermore, the
Federal Circuit’s Dolly ruling left potential for obtaining a patent
on a cloned animal.50 Minor differences of the extinct animal’s
DNA or cellular structure are likely to be enough to demonstrate
that the new animal is distinct from the parent organism. The
fragile nature of extinct animal DNA allows for multiple avenues
of differentiation from the original animal.
Myriad’s ruling that non-naturally occurring synthetically
produced strands of DNA are patentable supports the patent
eligibility of extinct animals.51 Transgenic de-extinction processes
depend on creating synthetic strands of DNA and splicing them
together with naturally occurring DNA to replicate the DNA
structure of the extinct animal. Although the goal is to replicate the
extinct animal’s DNA, it will not create a naturally occurring
genome. Indeed, the degradation of the original species’ DNA
makes it impossible to determine how close or different the two
genomes are.
The fact that the resultant animal is a re-creation of an animal
that no longer exists naturally further lends support to its patent
eligibility. The state of being extinct may place the animal outside
the category of a “product of nature.” An extinct animal’s species
by definition does not exist in nature. As such, it is no longer
naturally occurring. The re-created animal is fundamentally
distinct because it cannot be compared to a current composition in
nature.
The hurdle for obtaining patents on an animal brought back
through de-extinction is whether it will fall outside the Product of
Nature doctrine. Re-created extinct animals will likely fall outside
the Products of Nature doctrine because they are distinctly
49

See, e.g., U.S. Patent No. 4,736,866 (filed June 22, 1984) (transgenic nonhuman eukaryotic animal whose germ cells and somatic cells contain active
oncogene sequence); U.S. Patent No. 5,574,206 (filed Aug. 24, 1994)
(transgenic mouse used for HIV research); U.S. Patent No. 5,602,301 (filed
Nov. 16, 1994) (animal with successful graft specific to myocardial tissue); U.S.
Patent No. 7,550,649 (filed Oct. 28, 2004) (transgenic mouse used in
Parkinson’s Disease research).
50
In re Roslin Inst., 750 F.3d 1333 (Fed. Cir. 2014)
51
Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107,
2115–2120 (2013).
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different than a naturally occurring animal. For the above reasons,
initial animals produced as a result of de-extinction processes will
likely be deemed patent eligible subject matter under current U.S.
patent law.
B. The Arguments Against Patent Eligibility
Granting patents for animals has not been without controversy.
Many groups are concerned about the potential ramifications of
allowing animals to be patented as evidenced in the Animal Legal
Defense Fund suit. Growing discontent in corporate ownership of
plant patents has increased public skepticism of “owning” living
organisms.52 Obtaining patents on animals intended for release into
nature is likely to be met with more resistance and challenge.
Despite the likelihood that de-extinct animals will be deemed
patent eligible subject matter under existing law, the scope of such
patent protection is unclear. Patents for the first generation of
organisms may survive the Products of Nature doctrine, but what
about their offspring? The patent eligibility for the offspring of two
transgenic re-created animals could be ripe for controversy under
the Products of Nature doctrine. Can a wild animal, born of natural
sexual reproduction fall outside the definition of a “product of
nature” simply because its progenitor was the result of genetic
engineering?
C. The Novelty of Re-Creation
Although transgenic animals may meet the criteria for
patentable subject matter, there may be other barriers to obtaining
52

See, e.g., Campaigns – Animal Patents, AMERICAN ANTI-VIVISECTION
SOCIETY, http://aavs.org/our-work/campaigns/animal-patents (last visited Dec.
20, 2015); About no patents on seeds, NO PATENTS ON SEEDS, https://nopatents-on-seeds.org/en/about-us/about-no-patents-seeds (last visited Dec. 3,
2015); and Andrew B. Perzigian, Detailed Discussion of Genetic Engineering
and Animal Rights: The Legal Terrain and Ethical Underpinnings, ANIMAL
LEGAL AND HISTORICAL CENTER, MICH. ST. UNIV. COLLEGE OF LAW (2003),
available at https://www.animallaw.info/article/detailed-discussion-geneticengineering-and-animal-rights-legal-terrain-and-ethical (last visited Dec. 3,
2015).
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patent protection. Patent eligibility requires the invention be new,
non-obvious, and useful in addition to being patentable subject
matter.53 A patent cannot be obtained if “the claimed invention was
. . . otherwise available to the public before the filing date of the
claimed invention.”54 Additionally, a patent will be denied “if the
differences between the claimed invention and the prior art are
such that the claimed invention as a whole would have been
obvious before the effective filing date of the claimed invention to
a person having ordinary skill in the art to which the claimed
invention pertains.”55 The core purpose of de-extinction is to bring
back an animal that previously existed in nature. Many of the
arguments justifying transgenic animals as patent eligible subject
matter extend to defending that they are new and non-obvious, but
a full discussion of this issue exceeds the scope of this Article.
In many ways the movement to re-create previously extinct
animals underscores the purpose of the patent system “[t]o
promote the Progress of Science and useful Arts . . . .”56 Scientists
and visionaries are actively collaborating to push the boundaries of
science for the benefit of humanity. Patent protection creates
further incentive to engage and invest in biotechnology. In
exchange for the limited monopoly granted by a patent, the public
is rewarded by the re-introduction of unique and beneficial species
and the disclosure of how they were created.57 Despite these
benefits, successful recreation of a previously extinct animal is
likely to generate public debate and scrutiny. In the face of public
pressure, Congress has the ability to draft legislation to explicitly
allow or limit patent eligibility for animals. For example, in the
2011 America Invents Act, Congress put limitations on
patentability for human organisms.58 With enough pressure and
53

See, e.g., 1-3 CHISUM ON PATENTS § 3.01 (2015); 1-4 CHISUM ON
PATENTS § 4.01(2015); 1-5 CHISUM ON PATENTS § 5.01 (2015).
54
35 U.S.C. § 102 (a)(1) (2000).
55
35 U.S.C. § 103.
56
U.S. CONST. art. I, § 8, cl. 8.
57
JOHN G. SPRANKLING & RAYMOND R. COLETTA, PROPERTY: A
CONTEMPORARY APPROACH (2nd ed. 2012).
58
Leahy-Smith America Invents Act (AIA), Pub. L. 112-29, § 33(a), 125
Stat. 284, 340 (2011) (“Notwithstanding any other provision of law, no patent
may issue on a claim directed to or encompassing a human organism.”).
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media attention it is possible that the ability to patent a pigeon or
woolly mammoth will ultimately be decided on Capitol Hill.
CONCLUSION
De-extinction offers the possibility of returning previously
extinct animals to the planet, but the ability of scientist-creators to
own the patent rights to these animals is uncertain. At this time,
these organisms seem to fall within the scope of patent eligible
subject material. With success brings publicity, and an application
for a patent on the dodo, passenger pigeon, or woolly mammoth
may result in controversy and possibly congressional limits. But
absent congressional action, a carefully drafted application,
mindful of the margins of the law, may result in a patent that can
sustain subject matter challenge in the courts.
PRACTICE POINTERS


To fall outside the Product of Nature doctrine, a patent
application for a clone of a previously extinct animal needs
to specify how the resulting animal is fundamentally
different from the parent.



In the absence of congressional intervention, a transgenic
animal that was previously extinct will likely be patent
eligible so long as it remains genetically distinct from the
original animal.

